Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorofenidone
- Development stage
- Phase 2
- Lead developer
- Hainan Haiyao
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fluorofenidone (AKF-PD) is a novel pyridone small molecule with demonstrated anti-fibrotic and anti-inflammatory properties. It has shown efficacy in experimental models of hepatic, renal, and pulmonary fibrosis by inhibiting key inflammatory and fibrotic pathways. The drug is currently under clinical investigation in China for liver fibrosis and chronic hepatitis B[2][4][6]. Its mechanisms include inhibition of TGF-β1 (Transforming growth factor beta 1), p38γ MAPK (p38 gamma mitogen-activated protein kinase), NF-κB signaling pathway, NADPH oxidase via the PI3K/Akt pathway, NALP3 inflammasome activation, IL-17 pathway modulation, and MKK4/JNK signaling[2][5][6]. Fluorofenidone also attenuates extracellular matrix deposition and reduces proinflammatory cytokine release.
- Brand names
- flufenidone
- Other names
- 1-[3-fluorophenyl]-5-methyl-2-(1H)-pyridone1-(3-fluorophenyl)-5-methyl-2-(1H)-pyridone
02
Targets
NOX4 (NADPH oxidase 4)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)TGFB1 (Transforming growth factor Beta-1 proprotein)MAPK12 (Mitogen-activated protein kinase 12)
Beyond the preview
Go deeper on fluorofenidone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorofenidone.